NGM Biopharmaceuticals, Inc. (NASDAQ:NGM – Get Rating) Director Group L. P. Column bought 100,070 shares of the company’s stock in a transaction dated Tuesday, January 10th. The stock was purchased at an average cost of $4.84 per share, for a total transaction of $484,338.80. Following the completion of the transaction, the director now owns 480,542 shares of the company’s stock, valued at $2,325,823.28. The acquisition was disclosed in a legal filing with the SEC, which is available at this link.
NGM Biopharmaceuticals Trading Up 5.0 %
Shares of NGM Biopharmaceuticals stock opened at $5.30 on Friday. The firm has a fifty day simple moving average of $5.23 and a 200-day simple moving average of $10.34. NGM Biopharmaceuticals, Inc. has a 1-year low of $2.92 and a 1-year high of $18.25. The stock has a market capitalization of $433.15 million, a price-to-earnings ratio of -2.72 and a beta of 1.23.
NGM Biopharmaceuticals (NASDAQ:NGM – Get Rating) last issued its quarterly earnings data on Thursday, November 3rd. The company reported ($0.59) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.61) by $0.02. NGM Biopharmaceuticals had a negative net margin of 264.09% and a negative return on equity of 50.12%. The business had revenue of $7.91 million during the quarter, compared to analysts’ expectations of $7.02 million. As a group, research analysts predict that NGM Biopharmaceuticals, Inc. will post -2.11 earnings per share for the current year.
Hedge Funds Weigh In On NGM Biopharmaceuticals
Analyst Upgrades and Downgrades
NGM has been the topic of a number of research analyst reports. Jefferies Financial Group downgraded shares of NGM Biopharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday, October 17th. Cowen reduced their target price on shares of NGM Biopharmaceuticals from $32.00 to $9.00 and set an “outperform” rating for the company in a research note on Tuesday, October 18th. Piper Sandler reduced their target price on shares of NGM Biopharmaceuticals to $4.00 in a research note on Thursday, October 20th. Cowen reduced their target price on shares of NGM Biopharmaceuticals from $32.00 to $9.00 and set an “outperform” rating for the company in a research note on Tuesday, October 18th. Finally, B. Riley reduced their target price on shares of NGM Biopharmaceuticals from $29.00 to $8.00 in a research note on Monday, October 17th. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $9.00.
About NGM Biopharmaceuticals
NGM Biopharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); and MK-3655, an agonistic antibody that activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase IIb clinical trials for use in the treatment of type 2 diabetes and NASH.
- Get a free copy of the StockNews.com research report on NGM Biopharmaceuticals (NGM)
- MarketBeat: Week in Review 01/09-01/13
- JPMorgan Chase Falls As Banks Brace For Recession
- Why is the Bed Bath & Beyond Stock Price up 261%?
- Roku Stock Price is Trending, Here’s Why
- Carvana Stock Rally, Here’s What You Need to Know
Receive News & Ratings for NGM Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NGM Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.